Targeted Oncology
@TargetedOnc
Oncology news and insights from leading researchers and cancer centers.
You might like
Check out this week's addition of the Targeted Pulse, our top 5 stories of the week delivered right to you!👩🔬
📽️WEEKEND WATCH: Christian S. Hinrichs, MD, offers his thoughts on the future of specialized cell therapies such as autologous tumor-infiltration lymphocyte cell therapy and engineered T cell receptor-T cells particularly in the community clinic setting. hubs.li/Q03Vrts40
🩺 Patients with non-muscle invasive #BladderCancer seek improved communication with providers about treatment options, highlighting a need for collaborative care discussions. #NMIBC #GUCancers #PatientCare #Healthcare hubs.li/Q03Vrw1z0
🧠 Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 #astrocytoma in recent trials. #BrainCancer #Glioma #NeuroOncology #SNO2025 hubs.li/Q03VnJkl0
The rolling NDA submission of zipalertinib to the #FDA has begun, showing promise as a treatment for advanced #NSCLC with EGFR mutations. #LungCancer hubs.li/Q03VnGqL0
🚨 BREAKING: The #FDA approves enfortumab vedotin and pembrolizumab for muscle-invasive #BladderCancer, significantly improving survival rates post-surgery. hubs.li/Q03VrKlg0
📹 WATCH: Dr. Christian Hinrichs @RutgersCancer emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes. #CellTherapy hubs.li/Q03VnGlq0
🔬 The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell #lymphoma patients. hubs.li/Q03VnC230
🔬 A clinical study reveals that combining third-generation tyrosine kinase inhibitors with azacitidine effectively treats chronic myeloid #leukemia, showing promising patient outcomes. hubs.li/Q03VnBTK0
#ESMO25: High LAG3 expression in metastatic #RenalCellCarcinoma enhances initial #immunotherapy response but does not improve long-term survival outcomes. hubs.li/Q03VnysM0
📣FDA News: The FDA has approved new denosumab biosimilars, denosumab-desu (Osvyrti and Jubereq), for the treatment of osteoporosis and management of skeletal-related events in cancer. 🔗: hubs.ly/Q03VhtWL0
🌐Findings from an early phase 2 clinical trial show that a novel combination therapy for patients with unresectable nonmetastatic locally advanced pancreatic cancer yielded promising median progression-free survival.✔️ Read the full results here: hubs.li/Q03VglfW0
📽️WATCH: Christian S. Hinrichs, MD, provides a brief overview of an ongoing phase 2 study assessing the clinical activity of immunotherapy with T cell receptor-T cells in patients with various metastatic human papillomavirus-associated cancers. 🔗: hubs.li/Q03VdRPL0
🔬Trial Results: Phase 4 MITO16A/MaNGO OV-2 clinical trial shows that high immune infiltration is associated with a shorter PFS in patients with epithelial ovarian cancer receiving first-line treatment with bevacizumab. 🔗: hubs.li/Q03Vd4XM0
📣FDA News: The FDA has granted an accelerated approval to sevabertinib for the treatment of adult patients with previously treated locally advanced or metastatic, nonsquamous non–small cell lung cancer.✔️ #OncologyNews #CancerResearch 🔗: hubs.li/Q03Vcvrr0
📣FDA News: The FDA has granted a traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for patients with newly diagnosed light chain amyloidosis. 🔗: hubs.li/Q03Vcrby0
🔬Neladalkib, an investigational anaplastic lymphoma kinase-selective inhibitor, showed encouraging preliminary efficacy in pretreated advanced ALK fusion-positive non–small cell lung cancer. 🔗: hubs.li/Q03Vcpd40
🚨 BREAKING: The #FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell #LungCancer. #SCLC hubs.li/Q03Vck1d0
FDA Approves Sevabertinib in HER2-Mutated Nonsquamous NSCLC targetedonc.com/view/fda-appro… #lungcancer #FDAapproved
FDA Approves Selumetinib for Adult NF1 With Plexiform Neurofibromas targetedonc.com/view/fda-appro… #oncology #FDAapproved
United States Trends
- 1. #HardRockBet 3,750 posts
- 2. Arsenal 255K posts
- 3. Tottenham 79.1K posts
- 4. #AskFFT 1,105 posts
- 5. Thomas Frank 4,564 posts
- 6. Mason Rudolph 2,749 posts
- 7. Merino 19.1K posts
- 8. Klay 41.9K posts
- 9. #ARSTOT 11.8K posts
- 10. #COYG 6,079 posts
- 11. Trossard 14.5K posts
- 12. Great for 60 N/A
- 13. Sean Tucker 1,073 posts
- 14. Emanuel Wilson N/A
- 15. Aaron Rodgers 5,818 posts
- 16. Full PPR 1,508 posts
- 17. #sundayvibes 7,681 posts
- 18. Good Sunday 84.7K posts
- 19. PEAKTOOZ 1,766 posts
- 20. NFL Sunday 7,509 posts
You might like
-
OncLive.com
@OncLive -
Annals of Oncology
@Annals_Oncology -
Journal of Clinical Oncology
@JCO_ASCO -
The Oncologist
@OncJournal -
Oncology Times
@OncologyTimes -
CancerNetwork®
@CancerNetwrk -
The ASCO Post
@ASCOPost -
FDA Oncology
@FDAOncology -
ACS Journal Cancer
@JournalCancer -
The Cancer Letter
@TheCancerLetter -
The Lancet Oncology
@TheLancetOncol -
JAMA Oncology
@JAMAOnc -
Oncology Tube
@oncologytube -
OncoAlert
@OncoAlert -
ASCO
@ASCO
Something went wrong.
Something went wrong.